chrX-120456650-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_002294.3(LAMP2):c.183+1G>A variant causes a splice donor change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 22)
Exomes 𝑓: 0.0 ( 0 hom. 0 hem. )
Failed GnomAD Quality Control
Consequence
LAMP2
NM_002294.3 splice_donor
NM_002294.3 splice_donor
Scores
1
3
1
Splicing: ADA: 1.000
2
Clinical Significance
Conservation
PhyloP100: 4.82
Genes affected
LAMP2 (HGNC:6501): (lysosomal associated membrane protein 2) The protein encoded by this gene is a member of a family of membrane glycoproteins. This glycoprotein provides selectins with carbohydrate ligands. It may play a role in tumor cell metastasis. It may also function in the protection, maintenance, and adhesion of the lysosome. Alternative splicing of this gene results in multiple transcript variants encoding distinct proteins. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, product NOT destroyed by NMD, known LOF gene, truncates exone, which is 0.09570154 fraction of the gene. Cryptic splice site detected, with MaxEntScore 4.4, offset of -30, new splice context is: acaGTacgc. Cryptic site results in inframe change. If cryptic site found is not functional and variant results in exon loss, it results in frameshift change.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant X-120456650-C-T is Pathogenic according to our data. Variant chrX-120456650-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 163816.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-120456650-C-T is described in Lovd as [Pathogenic]. Variant chrX-120456650-C-T is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LAMP2 | NM_002294.3 | c.183+1G>A | splice_donor_variant | ENST00000200639.9 | NP_002285.1 | |||
LAMP2 | NM_001122606.1 | c.183+1G>A | splice_donor_variant | NP_001116078.1 | ||||
LAMP2 | NM_013995.2 | c.183+1G>A | splice_donor_variant | NP_054701.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LAMP2 | ENST00000200639.9 | c.183+1G>A | splice_donor_variant | 1 | NM_002294.3 | ENSP00000200639 | P3 | |||
LAMP2 | ENST00000371335.4 | c.183+1G>A | splice_donor_variant | 1 | ENSP00000360386 | A1 | ||||
LAMP2 | ENST00000434600.6 | c.183+1G>A | splice_donor_variant | 1 | ENSP00000408411 | A1 | ||||
LAMP2 | ENST00000706600.1 | c.183+1G>A | splice_donor_variant | ENSP00000516464 |
Frequencies
GnomAD3 genomes Cov.: 22
GnomAD3 genomes
Cov.:
22
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 865456Hom.: 0 Cov.: 13 AF XY: 0.00 AC XY: 0AN XY: 241024
GnomAD4 exome
Data not reliable, filtered out with message: AC0
AF:
AC:
0
AN:
865456
Hom.:
Cov.:
13
AF XY:
AC XY:
0
AN XY:
241024
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 22
GnomAD4 genome
Cov.:
22
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Danon disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Apr 08, 2023 | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 163816). Disruption of this splice site has been observed in individuals with Danon disease and hypertrophic cardiomyopathy (PMID: 21415759, 27532257; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change affects a donor splice site in intron 2 of the LAMP2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in LAMP2 are known to be pathogenic (PMID: 21415759). - |
Hypertrophic cardiomyopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 30, 2020 | The c.183+1G>A variant in LAMP2 has been reported in at least 4 individuals with clinical features of Danon disease, including a reportedly de novo occurrence (Boucek 2011 PMID: 21415759, Alfares 2015 PMID: 25611685; Walsh 2017 PMID: 27532257; LMM internal data; Invitae pers. comm.). This variant has also been reported by other clinical laboratories in ClinVar (Variation ID 163816) and was absent from large population studies. This variant occurs within the canonical splice site (+/- 1,2) and is predicted to cause altered splicing leading to an abnormal or absent protein. Loss of function of the LAMP2 gene is an established disease mechanism in X-linked Danon disease. In summary, this variant meets criteria to be classified as pathogenic for X-linked Danon disease. ACMG/AMP Criteria applied: PVS1_Strong, PM2, PM6, PS4_Moderate. - |
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 27, 2023 | The c.183+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 2 of the LAMP2 gene. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. The stop codon in the predicted resulting transcript occurs in the 5' end ofthe LAMP2 gene. As such, this alteration may escape nonsense-mediated mRNAdecay and/or be prone to rescue by reinitiation (Rivas et al. Science. 2015 May 8;348(6235):666-9; Lindeboom et al. Nat Genet. 2016 Oct;48(10):1112-8; Rhee et al. Sci Rep. 2017 May 10;7(1):1653). The exact functional effect of this alteration is unknown; however, the impacted region is critical for protein function (Ambry internal data). This variant has been previously reported in a cohort of patients reported to have Danon disease, and in a hypertrophic cardiomyopathy cohort (Boucek D et al. Genet Med, 2011 Jun;13:563-8; Walsh R et al. Genet Med, 2017 Feb;19:192-203). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Uncertain
CADD
Pathogenic
DANN
Uncertain
FATHMM_MKL
Uncertain
D
MutationTaster
Benign
D;D;D;D;D
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DL_spliceai
Position offset: 1
Find out detailed SpliceAI scores and Pangolin per-transcript scores at